66761-55-5

Upstream product

• 65976-77-4 (3,5-dimethoxy-phenyl)-acetic acid ethyl ester 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 

Downstream Products

• 855417-72-0 (3,5-dioxo-cyclohexyl)-acetic acid 
• 15580-06-0 1-Phenylsulfonyl-3-(3.5-dihydroxy-phenyl)-propanon-⁽²⁾ 
• 66761-56-6 ethyl 2-(2-formyl-3,5-dihydroxyphenyl)acetate 
• 142588-33-8 (3,5-bis-benzyloxy-phenyl)-acetic acid ethyl ester 
• 321661-62-5 Cytosporone B 
• 15580-07-1 α-acetylorcinol 
• 66761-62-4 (2-Butyl-3,5-dimethoxy-phenyl)-acetic acid 
• 66761-61-3 3-(2-Ethoxycarbonylmethyl-4,6-dimethoxy-phenyl)-propionic acid 
• 66851-00-1 [3,5-Dimethoxy-2-(3-oxo-butyl)-phenyl]-acetic acid ethyl ester 
• 66761-60-2 (Z)-3-(2-Ethoxycarbonylmethyl-4,6-dimethoxy-phenyl)-acrylic acid 
• 66761-54-4 ethyl 2-(2-formyl-3,5-dimethoxyphenyl)acetate 
• 66761-57-7 (3,5-Dimethoxy-2-methyl-phenyl)-acetic acid ethyl ester 
• 66761-59-9 2-Formyl-3,5-dimethoxyphenylacetic acid 
• 66761-58-8 (3,5-dimethoxy-2-methyl-phenyl)-acetic acid 

Relevant academic research and scientific papers

Relative impact of 3- and 5-hydroxyl groups of cytosporone B on cancer cell viability

A novel and the shortest route, thus far, for preparing cytosporone B (Csn-B) is reported. Csn-B and two analogs were used to probe the importance of hydroxyl groups at the 3- and 5-positions of the Csn-B benzene ring in inhibiting the viability of human H460 lung cancer and LNCaP prostate cancer cells, inducing H460 cell apoptosis, and interacting with the NR4A1 (TR3) ligand-binding domain (LBD). These studies indicate that Csn-B and 5-Me-Csn-B, having a phenolic hydroxyl at the 3-position of their aromatic rings, had similar activities in inhibiting cancer cell viability and in inducing apoptosis, whereas 3,5-(Me)2-Csn-B was unable to do so. These results are in agreement with ligand-binding experiments showing that the interaction with the NR4A1 LBD required the presence of the 3-hydroxyl group. The Royal Society of Chemistry.

Total synthesis of Cytosporone B

The total synthesis of Cytosporone B, a naturally occurring agonist for Nur77, has been accomplished. The key steps are the sequential Grignard reaction and Lemieux-van Rudloff oxidation followed by a deprotection of the methyl aromatic ether to phenol an

SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY

Monocyclic aryl compounds having selective LTB 4 antagonists properties and comprising an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent, therapeutic compositions and methods of treatment of disorders which result from LTB. sub.4 activity using the monocyclic aryl compounds are disclosed.